RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902
identified in the phase 1 to treat subjects with triple negative breast cancer.